Clinical Trials Directory

Trials / Completed

CompletedNCT03093519

A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease

A Phase 1 Randomized, Double-blind, Placebo-controlled, Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
21 (actual)
Sponsor
Kyowa Kirin Co., Ltd. · Industry
Sex
All
Age
55 Years – 84 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of KHK6640, given as a repeated dose in Japanese patients with Mild to Moderate Alzheimer's Disease.

Conditions

Interventions

TypeNameDescription
DRUGKHK6640Intravenous administration
DRUGPlaceboIntravenous administration

Timeline

Start date
2017-03-03
Primary completion
2017-12-06
Completion
2017-12-06
First posted
2017-03-28
Last updated
2018-03-20

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT03093519. Inclusion in this directory is not an endorsement.